Active Ingredient(s): Belumosudil Mesylate
FDA Approved: * July 16, 2021
Pharm Company: * KADMON PHARMS LLC
Category: Immunosuppressive

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Rezurock Overview

Belumosudil, sold under the brand name Rezurock, is used for the treatment of chronic graft versus host disease (cGvHD).[1] It is in the class of drugs known as serine/threonine kinase inhibitors.[1] Specifically, it is an inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II).[3] Belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signaling pathways which play major roles i...

Read more Rezurock Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Rezurock Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Belumosudil Mesylate
  • Tablet: 200mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Belumosudil Mesylate or a similar ingredient: (1 result)